Revisiting Secondary Information Related to Pharmacogenetic Testing

Incidental or secondary findings have been a major part of the discussion of genomic medicine research and clinical applications. For pharmacogenetic (PGx) testing, secondary findings arise due to the pleiotropic effects of pharmacogenes, often related to their endogenous functions. Unlike the guide...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in genetics 2021-10, Vol.12, p.741395
1. Verfasser: Haga, Susanne B
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 741395
container_title Frontiers in genetics
container_volume 12
creator Haga, Susanne B
description Incidental or secondary findings have been a major part of the discussion of genomic medicine research and clinical applications. For pharmacogenetic (PGx) testing, secondary findings arise due to the pleiotropic effects of pharmacogenes, often related to their endogenous functions. Unlike the guidelines that have been developed for whole exome or genome sequencing applications for management of secondary findings (though slightly different from PGx testing in that these refer to detection of variants in multiple genes, some with clinical significance and actionability), no corresponding guidelines have been developed for PGx clinical laboratories. Nonetheless, patient and provider education will remain key components of any PGx testing program to minimize adverse responses related to secondary findings.
doi_str_mv 10.3389/fgene.2021.741395
format Article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_proquest_miscellaneous_2583313227</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_d00d45bd823341dfac93cc3bbdbbf516</doaj_id><sourcerecordid>2583313227</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-97f297fbc856aad53c4cfaa5786c0f02879398d0a7c31638e78a8b77ca7c65933</originalsourceid><addsrcrecordid>eNpVUctKBDEQDKKorH6AF5mjl12T6ckkcxFk8bEgKD7OoSePNTI70WRW8O_NuCoaCGkqXdWVFCFHjM4AZHPqlra3s5KWbCYqBg3fIvusrqupzND2n3qPHKb0QvOqGgCodskeVDVvoGb7ZH5v333yg--XxYPVoTcYP4pF70Jc4eBDX9zbDgdriiEUd8-YUR3GyYPXxaNNI_GA7Djskj38Pifk6fLicX49vbm9WszPb6Y6jxumjXBl3q2WvEY0HHSlHSIXstbU0VKKBhppKAoNrAZphUTZCqEzMNqFCVlsdE3AF_Ua_Sp7VQG9-gJCXCqM2VdnlaHUVLw1sswPZsahbkBraFvTto5n9Qk522i9rtuVNdr2Q8Tun-j_m94_q2V4V5IzwYBngZNvgRje1vkj1MonbbsOexvWSZVcAjAoS5Fb2aZVx5BStO53DKNqzFJ9ZanGLNUmy8w5_uvvl_GTHHwCzQiclA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2583313227</pqid></control><display><type>article</type><title>Revisiting Secondary Information Related to Pharmacogenetic Testing</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Haga, Susanne B</creator><creatorcontrib>Haga, Susanne B</creatorcontrib><description>Incidental or secondary findings have been a major part of the discussion of genomic medicine research and clinical applications. For pharmacogenetic (PGx) testing, secondary findings arise due to the pleiotropic effects of pharmacogenes, often related to their endogenous functions. Unlike the guidelines that have been developed for whole exome or genome sequencing applications for management of secondary findings (though slightly different from PGx testing in that these refer to detection of variants in multiple genes, some with clinical significance and actionability), no corresponding guidelines have been developed for PGx clinical laboratories. Nonetheless, patient and provider education will remain key components of any PGx testing program to minimize adverse responses related to secondary findings.</description><identifier>ISSN: 1664-8021</identifier><identifier>EISSN: 1664-8021</identifier><identifier>DOI: 10.3389/fgene.2021.741395</identifier><identifier>PMID: 34659361</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>clinical reporting ; education ; Genetics ; incidental (secondary) findings ; patient consent</subject><ispartof>Frontiers in genetics, 2021-10, Vol.12, p.741395</ispartof><rights>Copyright © 2021 Haga.</rights><rights>Copyright © 2021 Haga. 2021 Haga</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-97f297fbc856aad53c4cfaa5786c0f02879398d0a7c31638e78a8b77ca7c65933</citedby><cites>FETCH-LOGICAL-c465t-97f297fbc856aad53c4cfaa5786c0f02879398d0a7c31638e78a8b77ca7c65933</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517135/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517135/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34659361$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Haga, Susanne B</creatorcontrib><title>Revisiting Secondary Information Related to Pharmacogenetic Testing</title><title>Frontiers in genetics</title><addtitle>Front Genet</addtitle><description>Incidental or secondary findings have been a major part of the discussion of genomic medicine research and clinical applications. For pharmacogenetic (PGx) testing, secondary findings arise due to the pleiotropic effects of pharmacogenes, often related to their endogenous functions. Unlike the guidelines that have been developed for whole exome or genome sequencing applications for management of secondary findings (though slightly different from PGx testing in that these refer to detection of variants in multiple genes, some with clinical significance and actionability), no corresponding guidelines have been developed for PGx clinical laboratories. Nonetheless, patient and provider education will remain key components of any PGx testing program to minimize adverse responses related to secondary findings.</description><subject>clinical reporting</subject><subject>education</subject><subject>Genetics</subject><subject>incidental (secondary) findings</subject><subject>patient consent</subject><issn>1664-8021</issn><issn>1664-8021</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVUctKBDEQDKKorH6AF5mjl12T6ckkcxFk8bEgKD7OoSePNTI70WRW8O_NuCoaCGkqXdWVFCFHjM4AZHPqlra3s5KWbCYqBg3fIvusrqupzND2n3qPHKb0QvOqGgCodskeVDVvoGb7ZH5v333yg--XxYPVoTcYP4pF70Jc4eBDX9zbDgdriiEUd8-YUR3GyYPXxaNNI_GA7Djskj38Pifk6fLicX49vbm9WszPb6Y6jxumjXBl3q2WvEY0HHSlHSIXstbU0VKKBhppKAoNrAZphUTZCqEzMNqFCVlsdE3AF_Ua_Sp7VQG9-gJCXCqM2VdnlaHUVLw1sswPZsahbkBraFvTto5n9Qk522i9rtuVNdr2Q8Tun-j_m94_q2V4V5IzwYBngZNvgRje1vkj1MonbbsOexvWSZVcAjAoS5Fb2aZVx5BStO53DKNqzFJ9ZanGLNUmy8w5_uvvl_GTHHwCzQiclA</recordid><startdate>20211001</startdate><enddate>20211001</enddate><creator>Haga, Susanne B</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20211001</creationdate><title>Revisiting Secondary Information Related to Pharmacogenetic Testing</title><author>Haga, Susanne B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-97f297fbc856aad53c4cfaa5786c0f02879398d0a7c31638e78a8b77ca7c65933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>clinical reporting</topic><topic>education</topic><topic>Genetics</topic><topic>incidental (secondary) findings</topic><topic>patient consent</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Haga, Susanne B</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in genetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Haga, Susanne B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Revisiting Secondary Information Related to Pharmacogenetic Testing</atitle><jtitle>Frontiers in genetics</jtitle><addtitle>Front Genet</addtitle><date>2021-10-01</date><risdate>2021</risdate><volume>12</volume><spage>741395</spage><pages>741395-</pages><issn>1664-8021</issn><eissn>1664-8021</eissn><abstract>Incidental or secondary findings have been a major part of the discussion of genomic medicine research and clinical applications. For pharmacogenetic (PGx) testing, secondary findings arise due to the pleiotropic effects of pharmacogenes, often related to their endogenous functions. Unlike the guidelines that have been developed for whole exome or genome sequencing applications for management of secondary findings (though slightly different from PGx testing in that these refer to detection of variants in multiple genes, some with clinical significance and actionability), no corresponding guidelines have been developed for PGx clinical laboratories. Nonetheless, patient and provider education will remain key components of any PGx testing program to minimize adverse responses related to secondary findings.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>34659361</pmid><doi>10.3389/fgene.2021.741395</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1664-8021
ispartof Frontiers in genetics, 2021-10, Vol.12, p.741395
issn 1664-8021
1664-8021
language eng
recordid cdi_proquest_miscellaneous_2583313227
source DOAJ Directory of Open Access Journals; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects clinical reporting
education
Genetics
incidental (secondary) findings
patient consent
title Revisiting Secondary Information Related to Pharmacogenetic Testing
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T13%3A13%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Revisiting%20Secondary%20Information%20Related%20to%20Pharmacogenetic%20Testing&rft.jtitle=Frontiers%20in%20genetics&rft.au=Haga,%20Susanne%20B&rft.date=2021-10-01&rft.volume=12&rft.spage=741395&rft.pages=741395-&rft.issn=1664-8021&rft.eissn=1664-8021&rft_id=info:doi/10.3389/fgene.2021.741395&rft_dat=%3Cproquest_doaj_%3E2583313227%3C/proquest_doaj_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2583313227&rft_id=info:pmid/34659361&rft_doaj_id=oai_doaj_org_article_d00d45bd823341dfac93cc3bbdbbf516&rfr_iscdi=true